alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 18.445 Housing. ( a ) *Housing provided by a recipient.* A recipient that provides housing to its nonhandicapped students shall provide comparable, convenient, and accessible housing to qualified handicapped students at the same cost as to others. At the end of the transition period provided for in § 18.422(e), this housing shall be available in sufficient quantity and variety so that the scope of handicapped students' choice of living accommodations is, as a whole, comparable to that of nonhandicapped students.
( b ) *Other housing.* A recipient that assists any agency, organization, or person in making housing available to any of its students shall assure itself that such housing is, as a whole, made available in a manner that does not result in discrimination on the basis of handicap.
### Regulatory Evaluation Docket No. 

### FAA-FAA-2011-1411 Directorate Identifier: 2011-NM-074-AD

( (nm makt! clumKi!.\' 10 thi! \'(/lues in the lahle ln!lmr, you IIIllS! ensttrt! the totu/s updme

**accordi11g~v.** 

### (f theytlo nut , click (or Tab) imo andlhl.!n out of the changedcell. Estimated Costs: Action Costs per Product (e.g., aircraft, engine, (e.g., Inspection, propeller, appliance) Work-hours Labor Parts Cost Total Costs Number of Total Cost replacement) (include cost (labor + 

# u.s. for U.S. Fleet Do not include on- condition costs here access, testing, (@$85/h parts) Registered and close-up) our) Products 

### <same as existing " 

# l· lPI B AD actions> ; l

**~J)-'l:J/'1**

**hK~.** 

### ,, 

## '• ' 

# r I

'I 

### ' **~(t£,1"'""-**

**~Jr,lt-~** ' :)

**'lvv~p** 

### (\\_ (' 

## ,, }(i 

### > I IJ (:

**Yb1t{~** '> '2 

### 'Ji}

## flf I

**~~I** 1 ( r 

## J II :) 

## '' 'i 

### ' ' !] 

### '
\ 

### ' 

# ,. \ 

### ' The known number ofproducts in compliance: Total Costs ofcompliance for U.S. fleet: 

# s 0 Costs covered under warrantY (ifknown) $ 

## @ On-Condition Costs: __ Action Work-hours Labor cost Parts Cost Cost per Product (e.g.. Inspection, (include access, (@$85/hour)

replacement) testing, and closeup) 

### <same as existing 

### AD actions> Special considerations for Economic Analysis (Use thisfield to explain anything in the Estimated Costs table that was assumed ormight not be obvious. Thisfield can also be usedto explain warranty costs):

### Executive Order 12866: Could the AD be considered a "significant regulatory action" ?

# Q *Explanation: <same as existing 

### AD action> 

### DOT Regulatory Policies and Procedures: J'!fB'h 

### Is the AD significant?

**~** 

### *Explanation: <same as existing 

### AD action> 

### Regulatory Flexibility Act: YES*O

**NO~**


### YES*0

**NO~** 

### Will the 

### AD have a significant economic impact on a substantial number ofsmall entities? Explain for either a Yes orNo answer. - YES0

**NO~** 

### Explanation: <same 

### as existing

## AD action> 

### Intrastate Aviation in Alaska: This AD could affect intrastate aviation in Alaska. Is it appropriate to include specific requirements for aircraft operated in Alaska where aviation might be the only mode oftransportation?



# ~ YES*0

**NO~** 

### *Explanation: <same as existing 

### AD action>
§ 17.247 Determination process for placement of residents. Section 403 of Public Law 115-182 does not authorize a grant program or cooperative agreement program through which covered facilities or any other entity may apply for residents to be placed in covered facilities or to apply for VA to pay or reimburse costs under § 17.248. VA therefore will not conduct a public solicitation to determine those covered facilities in which residents may be placed or to determine costs that may be paid or reimbursed under § 17.248. VA will instead determine those covered facilities in which residents may be placed and determine any costs to be paid or reimbursed under § 17.248 in accordance with the following parameters: ( a ) VA Central Office will issue a request for proposal (RFP) to announce opportunities for residents to be placed in covered facilities and to have costs paid or reimbursed under § 17.248. This RFP will describe, at a minimum: ( 1 ) Consideration factors to include the criteria in § 17.246, that will be used to evaluate any responses to the RFP, as well as the relative importance of such consideration factors;
( 2 ) Information required to be in any responses to the RFP; and
( 3 ) The process to submit a response to the RFP.
( b ) Covered facilities will submit responses to the RFP to VA Central Office.
( c ) Consistent with paragraph (a) of this section, VA Central Office will evaluate responses to the RFP and will determine those covered facilities where residents may be placed and costs under § 17.248 are paid or reimbursed.
#### § 16.118 Applications and proposals lacking definite plans for involvement of human subjects.

Certain types of applications for grants, cooperative agreements, or contracts are submitted to Federal departments or agencies with the knowledge that subjects may be involved within the period of support, but definite plans would not normally be set forth in the application or proposal. These include activities such as institutional type grants when selection of specific projects is the institution's responsibility; research training grants in which the activities involving subjects remain to be selected; and projects in which human subjects' involvement will depend upon completion of instruments, prior animal studies, or purification of compounds. Except for research waived under § 16.101(i) or exempted under § 16.104, no human subjects may be involved in any project supported by these awards until the project has been reviewed and approved by the IRB, as provided in this policy, and certification submitted, by the institution, to the Federal department or agency component supporting the research.
<PAGE>

                                  EXHIBIT 32.1

              CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Comm Bancorp, Inc. (the "Company") on
Form 10-Q for the quarter ended June 30, 2003, as filed with the Securities and
Exchange Commission on the date therein specified (the "Report"), I, William F.
Farber, Sr., President and Chief Executive Officer of the Company, certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:

1.       The Report fully complies with the requirements of Section 13(a) or
         15(d) of the Securities Act of 1934, and

2.       The information contained in the Report fairly represents, in all
         material respects, the financial condition and results of operations of
         the Company.

Date: August 12, 2003                   /s/ William F. Farber, Sr.
                                        ----------------------------------------
                                        William F. Farber, Sr.
                                        President and Chief Executive Officer
                                        Chairman of the Board/Director
                                        (Principal Executive Officer)

A signed original of this written Statement required by Section 906 has been
provided to the Company and will be retained by the Company and furnished to the
Securities and Exchange Commission or its staff upon request.

                                       50
----

            COMMISSION DIRECTIVE 2005/34/EC

of 17 May 2005         

amending Council Directive 91/414/EEC to include etoxazole and tepraloxydim as active substances

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Council Directive 91/414/EEC of 15 July 1991 concerning the placing of plant protection products on the market (1), and in particular Article 6(1) thereof,

Whereas:

HAS ADOPTED THIS DIRECTIVE:

Article 1

Annex I to Directive 91/414/EEC is amended as set out in the Annex to this Directive.

Article 2

1.   Member States shall adopt and publish by 30 November 2005 at the latest the laws, regulations and administrative provisions necessary to comply with this Directive. They shall forthwith communicate to the Commission the text of those provisions and a correlation table between those provisions and this Directive.

They shall apply those provisions from 1 December 2005.

When Member States adopt those provisions, they shall contain a reference to this Directive or shall be accompanied by such a reference on the occasion of their official publication. Member States shall determine how such reference is to be made.

2.   Member States shall communicate to the Commission the text of the main provisions of national law which they adopt in the field covered by this Directive.

Article 3

1.   Member States shall review the authorisation for each plant protection product containing etoxazole or tepraloxydim to ensure that the conditions relating to those active substances set out in Annex I to Directive 91/414/EEC are complied with. Where necessary, they shall amend or withdraw authorisations in accordance with Directive 91/414/EEC by 30 November 2005 at the latest.

2.   For each authorised plant protection product containing etoxazole or tepraloxydim as either the only active substance or as one of several active substances all of which were listed in Annex I to Directive 91/414/EEC by 31 May 2005 at the latest, Member States shall re-evaluate the product in accordance with the uniform principles provided for in Annex VI to Directive 91/414/EEC, on the basis of a dossier satisfying the requirements of Annex III to that Directive. On the basis of that evaluation, they shall determine whether the product satisfies the conditions set out in Article 4(1)(b), (c), (d) and (e) of Directive 91/414/EEC.

Following that determination Member States shall:

Article 4

This Directive shall enter into force on 1 June 2005.

Article 5

This Directive is addressed to the Member States.

Done at Brussels, 17 May 2005.

For the Commission

Markos KYPRIANOU            

Member of the Commission

----

(1)OJ L 230, 19.8.1991, p. 1. Directive as last amended by Directive 2005/25/EC (OJ L 90, 8.4.2005, p. 1).

(2)OJ L 14, 19.1.1999, p. 30.

(3)OJ L 228, 15.8.1998, p. 35.

----

ANNEX

In Annex I to Directive 91/414/EEC, the following rows are added at the end of the table:

----

(*1)  Further details on identity and specification of active substances are provided in the review report.’         

----
§ 17.61 Eligibility. VA health care personnel may assist a veteran by referring such veteran for placement in a privately or publicly-owned community residential care facility if: ( a ) At the time of initiating the assistance: ( 1 ) The veteran is receiving VA medical services on an outpatient basis or VA medical center, domiciliary, or nursing home care; or
( 2 ) Such care or services were furnished the veteran within the preceding 12 months;
( b ) The veteran does not need hospital or nursing home care but is unable to live independently because of medical (including psychiatric) conditions and has no suitable family resources to provide needed monitoring, supervision, and any necessary assistance in the veteran's activities of daily living and instrumental activities of daily living ; and
( c ) The facility has been approved in accordance with § 17.63 of this part.
[54 FR 20842, May 15, 1989. Redesignated and amended at 61 FR 21965, 21966, May 13, 1996; 84 FR 33696, July 15, 2019]
§ 404.8 Application for a license. ( a ) An application for a license should be addressed to the Federal agency having custody of the invention and shall normally include: ( 1 ) Identification of the invention for which the license is desired including the patent application serial number or patent number, title, and date, if known;
( 2 ) Identification of the type of license for which the application is submitted;
( 3 ) Name and address of the person, company, or organization applying for the license and the citizenship or place of incorporation of the applicant;
( 4 ) Name, address, and telephone number of the representative of the applicant to whom correspondence should be sent;
( 5 ) Nature and type of applicant's business, identifying products or services which the applicant has successfully commercialized, and approximate number of applicant's employees;
( 6 ) Source of information concerning the availability of a license on the invention;
( 7 ) A statement indicating whether the applicant is a small business firm as defined in § 404.3(c);
( 8 ) A detailed description of applicant's plan for development or marketing of the invention, or both, which should include: ( i ) A statement of the time, nature and amount of anticipated investment of capital and other resources which applicant believes will be required to bring the invention to practical application;
( ii ) A statement as to applicant's capability and intention to fulfill the plan, including information regarding manufacturing, marketing, financial, and technical resources;
( iii ) A statement of the fields of use for which applicant intends to practice the invention; and
( iv ) A statement of the geographic areas in which applicant intends to manufacture any products embodying the invention and geographic areas where applicant intends to use or sell the invention, or both;
( 9 ) Identification of licenses previously granted to applicant under federally owned inventions;
( 10 ) A statement containing applicant's best knowledge of the extent to which the invention is being practiced by private industry or Government, or both, or is otherwise available commercially; and
( 11 ) Any other information which applicant believes will support a determination to grant the license to applicant.
( b ) An executed CRADA which provides for the use for research and development purposes by the CRADA collaborator under that CRADA of a Federally-owned invention in the Federal laboratory's custody (pursuant to 35 U.S.C. 209 and 15 U.S.C. 3710a(b)(1)), and which addresses the information in paragraph (a) of this section, may be treated by the Federal laboratory as an application for a license.
[83 FR 15963, Apr. 13, 2018]
§ 14.630 Authorization for a particular claim. ( a ) Any person may be authorized to prepare, present, and prosecute one claim. A power of attorney executed on VA Form 21-22a, “Appointment of Attorney or Agent as Claimant's Representative,” and a statement signed by the person and the claimant that no compensation will be charged or paid for the services, shall be filed with the agency of original jurisdiction where the claim is presented. The power of attorney identifies to VA the claimant's appointment of representation and authorizes VA's disclosure of information to the person representing the claimant.
( b ) Representation may be provided by an individual pursuant to this section one time only. An exception to this limitation may be granted by the General Counsel in unusual circumstances. Among the factors which may be considered in determining whether an exception will be granted are: ( 1 ) The number of accredited representatives, agents, and attorneys operating in the claimant's geographic region;
( 2 ) Whether the claimant has unsuccessfully sought representation from other sources;
( 3 ) The nature and status of the claim; and
( 4 ) Whether there exists unique circumstances which would render alternative representation inadequate.
( c ) Persons providing representation under this section must comply with the laws administered by VA and with the regulations governing practice before VA including the rules of conduct in § 14.632 of this part.
( d ) Persons providing representation under this section are subject to suspension and or exclusion from representation of claimants before VA on the same grounds as apply to representatives, agents, and attorneys in § 14.633 of this part.
( e ) With respect to the limitation in paragraph (b) of this section, a person who had been authorized under paragraph (a) of this section to represent a claimant who later dies and is replaced by a substitute pursuant to 38 CFR 3.1010 for purposes of processing the claim to completion will be permitted to represent the substitute if the procedures of § 14.631(g) are followed.
(Authority: 38 U.S.C. 501(a), 5121A, 5903)
[68 FR 8546, Feb. 24, 2003, as amended at 73 FR 29872, May 22, 2008; 79 FR 52983, Sept. 5, 2014]
#### § 17.633 Deferment of obligated service.

Deferment of obligated service under the VIOMPSP is treated in the same manner as deferment of obligated service under the HPSP under § 17.608.

(Authority: 38 U.S.C. 7504(3))
###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 2 is placed in the separate grouping of parts pertaining to trademarks regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 6 is placed in the separate grouping of parts pertaining to trademarks regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 7 is placed in the separate grouping of parts pertaining to trademarks regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 1 is placed in the separate grouping of parts pertaining to patents regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 3 pertaining to both patents and trademarks is placed in the grouping pertaining to patents regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 4 is placed in the separate grouping of parts pertaining to patents regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 5 is placed in the separate grouping of parts pertaining to patents regulations.

#### § 42.56 Expungement of confidential information.

After denial of a petition to institute a trial or after final judgment in a trial, a party may file a motion to expunge confidential information from the record.
Exhibit 32.2

                            CERTIFICATION PURSUANT TO
                        SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of Tofutti Brands Inc. (the "Company")
on Form 10-QSB for the period ending June 28, 2003 as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Steven Kass, Chief
Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as
adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

        (1) The Report fully complies with the requirements of section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

        (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the
Company.


/s/Steven Kass*
---------------
Steven Kass
Chief Financial Officer
August 18, 2003



* The originally executed copy of this Certification will be maintained at the
Company's offices and will be made available for inspection upon request.
----

Notice of the date of entry into force of the Additional Protocol to the Economic Partnership, Political Coordination and Cooperation Agreement between the European Community and its Member States, of the one part, and the United Mexican States, of the other part, to take account of the accession of new Member States to the European Union

The contracting parties having notified one another of the completion of the procedures required for entry into force of the Additional Protocol to the Economic Partnership, Political Coordination and Cooperation Agreement, as approved by the Council of the European Union at its meeting on 31 January 2005, the Additional Protocol will enter into force with effect from 1 February 2005, in accordance with Article 5(2) thereof.

----
#### § 1.521 Special restrictions concerning social security records.

Information received from the Social Security Administration may be filed in the veteran's claims folder without special provisions. Such information will be deemed privileged and may not be released by the Department of Veterans Affairs except that information concerning the amount of social security benefits paid to a claimant or the amount of social security tax contributions made by the claimant may be disclosed to the claimant or his or her duly authorized representative. Any request from outside the Department of Veterans Affairs for other social security information will be referred to the Social Security Administration for such action as they deem proper.

[27 FR 9599, Sept. 28, 1962]
41528.

#### TURNER v. ASSOCIATED INDEMNITY CORPORATION.

Argued September 14, 1965

Decided January 31, 1966

Rehearing denied February 23, 1966.

*Northcutt <& Edwards, W. S. Northcutt,*for plaintiff in error.

*Smith, Ringel, Martin & Lowe, Sam F. Lowe, Jr., Ralph H. Witt,*contra.

Bell, Presiding Judge.

This is an action to recover upon an automobile liability insurance policy on account of injuries and damages to the plaintiff insured resulting from an automobile collision with a known uninsured motorist. The policy by its terms undertook “to pay all sums which the insured or his legal representative shall be legally entitled to recover as damages from the owner or operator of an uninsured automobile,” as required by Ga. L. 1963, p. 588. The reasoning and the construction stated in *State Farm Mut. Auto. Ins. Co. v. Girtman,*113 Ga. App. 54 (147 SE2d 364), are applicable and controlling in this case. *Girtman*held that before suit could be brought against the insurer under this kind of coverage, it was an essential condition precedent that suit must first be brought and judgment recovered against the known uninsured motorist. As the petition here fails to show compliance with this condition, the trial court did not err in sustaining defendant’s general demurrers and dismissing the plaintiff’s petition.

*Judgment affirmed.*

*Frankum and Hall, JJ., concur.*